MARKET

ALNY

ALNY

Alnylam Pharmaceuticals Inc
NASDAQ
147.00
-0.43
-0.29%
Pre Market: 147.00 0 0.00% 05:37 02/20 EST
OPEN
148.00
PREV CLOSE
147.43
HIGH
150.93
LOW
146.82
VOLUME
50
TURNOVER
0
52 WEEK HIGH
227.91
52 WEEK LOW
143.52
MARKET CAP
18.51B
P/E (TTM)
-41.7069
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at ALNY last week (0212-0216)?
Weekly Report · 1d ago
Maintaining Hold on Alnylam Pharmaceuticals Amid Clinical and Financial Uncertainties
Analyst Mani Foroohar of Leerink Partners maintained a Hold rating on Alnylam Pharma (ALNY – Research Report) with a price target of $136.00. The firm’s recent announcement concerning the Phase 3 HELIOS-B study of vutrisiran in ATTR-cardiomyopathy.
TipRanks · 1d ago
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Just Released Its Full-Year Earnings: Here's What Analysts Think
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) reported its yearly results last week. Revenues came in at US$1.8b and the company reported a statutory loss of US$3.52 per share. The analysts have updated their forecasts for the company for next year. The consensus is now expecting revenues to be lower than last year, and per-share losses to rise. The company's share price has dropped 14% since the report, to US$147.
Simply Wall St · 2d ago
Alnylam Pharmaceuticals’ New Regulation Risk – A Cause for Worry?
TipRanks · 3d ago
Alnylam (ALNY) Q4 Loss Narrower Than Expected, Stock Dips 10%
NASDAQ · 4d ago
Goldman Sachs Downgrades Alnylam Pharmaceuticals: Here's What You Need To Know
Goldman Sachs downgraded its rating of Alnylam Pharmaceuticals to Neutral with a price target of $173.00. The company is a leader in the study of RNA interference (RNAi) therapeutics. Shares of alnylam pharmaceuticals are trading up 0.41% over the last 24 hours.
Benzinga · 4d ago
RBC Capital Reiterates Outperform on Alnylam Pharmaceuticals, Maintains $235 Price Target
Benzinga · 4d ago
Agios (AGIO) Q4 Earnings & Revenues Fall Short of Estimates
NASDAQ · 4d ago
More
About ALNY
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid interference (RNAi). Its pipeline includes five marketed products and over ten clinical programs, including several in late-stage development, across four strategic therapeutic areas (STArs): genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and CNS/ocular diseases. Its RNAi-based medicines include ONPATTRO (patisiran), AMVUTTRA (vutrisiran), GIVLAARI (givosiran), OXLUMO (lumasiran) and Leqvio (inclisiran). ONPATTRO is an intravenously administered RNAi therapeutic targeting transthyretin amyloidosis. GIVLAARI is used to reduce induced liver aminolevulinic acid synthase 1 messenger RNA (mRNA), to reduce toxins associated with attacks and other disease manifestations of acute hepatic porphyria. OXLUMO is an RNAi therapeutic targeting hydroxyacid oxidase 1 for the treatment of primary hyperoxaluria type 1.

Webull offers Alnylam Pharmaceuticals, Inc. stock information, including NASDAQ: ALNY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALNY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALNY stock methods without spending real money on the virtual paper trading platform.